Sarepta Therapeutics Inc (SRPT) Stock: “Eteplirsen Approval Controversy Rages On”

If you follow Sarepta Therapeutics Inc (NASDAQ:SRPT), you know about Eteplirsen. The treatment is designed to treat several diseases, including Duchenne muscular dystrophy. Recently, the FDA granted accelerated approval for the treatment. However, finalized approval is still in question and SRPT investors aren’t sure what to expect.

What’s Happening

Recently, an interesting tweet came across the wire. The tweet, authored by Alicia Ault, said the following…

Eteplirsen approval controversy rages on. FDA’s J Jenkins just spent 20 mins savaging Sarepta’s data and process. #NordSummit #Duchenne”

What We’re Seeing From SRPT

Regardless of the Tweet, with regard to Sarepta Therapeutics Inc (NASDAQ:SRPT), the bulls seem to outweigh the bears in a pool that’s not worried about the hype. Currently (2:10), the stock is trading at $50.85 Per share after a gain of $1.91 Per share or 3.90% thus far today.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


What’s Next

Right now, things are really up in the air. The truth is that Sarepta Therapeutics Inc (NASDAQ:SRPT) needs Eteplirsent to reach finalized approval, and controversy surrounding the approval could be concerning. Nonetheless, the treatment has proven through multiple trials to be effective. Considering the accelerated approval, we know that there’s something positive to it, giving it a higher chance of finalized approval. All in all, I am expecting for the FDA to approve the treatment, leading to big gains in the long run.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Don’t Miss The News

CNA Finance offers a free subscription where you get the news as fast as we can dig it up. Never miss the news again, subscribe for free.

Note: This article was written by Joshua Rodriguez, owner and founder of CNA Finance. If you would like to connect with Joshua, you can do so by emailing him at!